Coeptis Therapeutics Inc COEP:OTCPK

RT Quote | Exchange | USD
Last | 08/12/22 EDT
2.20quote price arrow down-0.05 (-2.22%)
Volume
12,410
52 week range
1.69 - 14.00
Loading...
  • Open2.10
  • Day High2.25
  • Day Low2.00
  • Prev Close2.25
  • 52 Week High14.00
  • 52 Week High Date01/11/22
  • 52 Week Low1.69
  • 52 Week Low Date08/09/22

Key Stats

  • Market Cap85.82M
  • Shares Out39.01M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.55
  • YTD % Change-45.68

KEY STATS

  • Open2.10
  • Day High2.25
  • Day Low2.00
  • Prev Close2.25
  • 52 Week High14.00
  • 52 Week High Date01/11/22
  • 52 Week Low1.69
  • 52 Week Low Date08/09/22
  • Market Cap85.82M
  • Shares Out39.01M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.55
  • YTD % Change-45.68

RATIOS/PROFITABILITY

  • EPS (TTM)-1.02
  • P/E (TTM)-2.17
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-34.317M
  • ROE (TTM)-1,166.49%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)100.00%
  • Net Margin (TTM)-17,932.39%
  • Debt To Equity (MRQ)184.99%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Coeptis Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Coeptis Therapeutics, Inc. is a biopharmaceutical company. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The Company's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its...
Address
105 Bradford Rd, Suite 420
Wexford, PA
15090
United States